Previous 10 | Next 10 |
home / stock / slncf / slncf news
2024-03-13 10:01:09 ET Silence Therapeutics plc (SLN) Q4 2023 Earnings Conference March 13, 2024 08:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda...
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to host conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN (“Silence” or ...
Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will r...
2024-02-24 20:53:46 ET Summary Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by ...
Silence Therapeutics plc (Nasdaq: SLN) (“ Silence ” or the “ Company ”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced an oversub...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will partic...
Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company comm...
2023-11-17 07:38:01 ET More on Virpax Pharmaceuticals Seeking Alpha’s Quant Rating on Virpax Pharmaceuticals Historical earnings data for Virpax Pharmaceuticals Financial information for Virpax Pharmaceuticals For further details see: Virpax Pharma...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...